Literature DB >> 31166

Premedication with lorazepam for bronchoscopy under general anaesthesia.

J M Hewitt, A M Barr.   

Abstract

Lorazepam 3 or 4 mg i.m. was given to 100 patients as premedication before bronchoscopy under thiopentone-suxamethonium anaesthesia. Forty-nine of the patients assessed as anxious received oral lorazepam as preoperative night sedation also. Lorazepam was an effective night sedative. Forty-two of the 49 patients slept well and were calm and co-operative in the morning. Following the i.m. injection of lorazepam, 64% of patients had complete lack of recall for 4--10 h following premedication. Only 5% recalled correctly a simple objective test of memory initiated in the anaesthetic room. The frequency of recall was higher in those who consumed alcohol regularly and in females. There was one case of awareness during bronchoscopy in a patient who received only a small dose of lorazepam (2.8 mg per 70 kg). Side-effects were minimal and patient acceptance was impressive. These results show an advance on previous studies using pethidine and diazepam. Further improvement is needed, particularly in adjusting the dose of lorazepam to body weight and to factors such as age, sex and alcohol intake.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 31166     DOI: 10.1093/bja/50.11.1149

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  3 in total

Review 1.  Lorazepam: a review of its clinical pharmacological properties and therapeutic uses.

Authors:  B Ameer; D J Greenblatt
Journal:  Drugs       Date:  1981-03       Impact factor: 9.546

2.  Comparative Study Between Oral Lorazepam and Diazepam as Sedation in Oral and Maxillofacial Surgery.

Authors:  Vikas Sharma; Amaninder Singh; Parul Sharma; Simranjeet Kaur; Akanksha Zutshi
Journal:  J Maxillofac Oral Surg       Date:  2018-03-05

3.  Anaesthesia for bronchoscopy: examination of a standard technique.

Authors:  J P Newell; J M Collis
Journal:  J R Soc Med       Date:  1980-04       Impact factor: 18.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.